Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
Clinical trial NCT05238649 · UNKNOWN
Trial details
- NCT number
- NCT05238649
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-10
- Primary completion
- 2022-11-30
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.